🏆 Deal of the Week · CW 19/2026
CellCentric raised USD 220 million in a Series D round; the company's valuation was not disclosed. The round was led by Venrock.
CellCentric — key deal facts
| Company | CellCentric |
| Founded | 2003 |
| Headquarters | Cambridge, United Kingdom |
| Amount raised | USD 220m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series D |
| Investors | The round was led by Venrock |
| Sectors | BioTech, Biotechnology |
Who invested in CellCentric?
The Series D was led by Venrock, a long-established life sciences and technology venture firm. The involvement of a dedicated biotech investor of Venrock's profile signals conviction in CellCentric's clinical programme at a pivotal Phase II stage.
What does CellCentric do?
CellCentric is a clinical-stage biotechnology company headquartered in Cambridge, United Kingdom, at Chesterford Research Park. Founded in 2003 and later spun out of the University of Cambridge, the company focuses on oncology therapeutics. Its lead asset, inobrodib, is a first-in-class oral p300/CBP inhibitor currently in Phase II clinical trials for the treatment of multiple myeloma and other cancers. CellCentric's mission is to transform outcomes for cancer patients through the targeted clinical development of inobrodib.
CellCentric valuation & multiples
CellCentric operates at the intersection of biotechnology and pharmaceuticals, developing innovative therapeutic solutions across the oncology space. Based on European benchmarks for Q1 2026, comparable biotechnology and pharmaceutical businesses trade at EV/Sales multiples of 3.61x to 4.99x and EV/EBITDA multiples of 17.86x to 20.68x. Investors seeking deeper context on sector valuation can explore the full biotechnology and pharmaceutical multiples pages on DealMatrix.
Explore the benchmarks: Series D.
Frequently asked questions
How much did CellCentric raise in its Series D?
CellCentric raised USD 220 million in its Series D round.
What is CellCentric's valuation?
CellCentric's valuation was not disclosed in connection with this Series D financing.
Who invested in CellCentric?
The Series D round was led by Venrock.
When was CellCentric founded and where is it based?
CellCentric was founded in 2003 and is headquartered in Cambridge, United Kingdom.
Source: original announcement — read the full report.